Key Highlights

  • The shares traded at USD 0.2060 in pre-market hours on Friday, November 13, 2026, down 7.21%, and no company statement issued between November 11 and 13 was found to explain the change.
  • Published data had the stock sliding to USD 0.1450 on October 19, 2026, a 12.01% decline, so the present quote is roughly 42% above that low (calculated), signaling a rebound within a choppy range.
  • Over the past 52 weeks the shares moved between USD 0.1110 and USD 5.2290 in published figures; about 2.41 million shares are outstanding, implying a Market Value near USD 349,000 at the October price.
  • A planned combination with Roosevelt Resources was called off in December 2025, and a USD 4 million private Placement was completed on June 13, 2026.

A Pullback After a Rebound, Without a Fresh Notice

Arcadia Biosciences (NASDAQ:RKDA) was marked 7.21% lower at USD 0.2060 in pre-market dealing on November 13, 2026. Back-calculating from that quote puts the previous level near USD 0.2220 (calculated), well over the October 19 finish of USD 0.1450, when the stock lost 12.01%. Searches did not locate a press release or filing from November 11 to 13 that accounts for either swing. Sub-USD 1 shares can be moved by a handful of trades, spreads are often wide and quotes can turn around, so the 7.21% reflects pre-market conditions only. Pre-market data on October 20 showed USD 0.1363, a reminder of how far the quote has travelled in just a few weeks.

Zola Coconut Water, Wheat Traits and an Abandoned Combination

Arcadia Biosciences (NASDAQ:RKDA) develops improved wheat crop traits, and its consumer lineup includes Zola coconut water, GoodWheat and ProVault. A 2025 plan to combine with Roosevelt Resources on an all-stock basis was terminated, a notice disclosed on December 26, 2025 and reaffirmed alongside full-year figures on March 26, 2026. The third quarter of 2025 produced USD 1.30 million of revenue, measured against USD 1.54 million, while cash stood at USD 1.1 million. The company release credited Zola with an 18% jump in Volume during the first quarter of 2026. Gross Margin stayed above 30% for 11 consecutive quarters through the third quarter of 2025, although the team is small, so a few customers can swing volumes within a quarter.

A USD 4 Million Placement, a Resale Registration and Share Count Doubts

Arcadia Biosciences (NASDAQ:RKDA) unveiled a USD 4 million private placement on June 12, 2026, priced at market in line with Nasdaq rules, and it was completed on June 13. A published summary placed cash near USD 4.2 million at the end of the second quarter, with operating cash use of USD 319,000, but that number rests on a single summary. Data also showed a resale registration for 11.92 million shares, which clashes with the 2.41 million shares listed as outstanding, so the count is unreconciled. Third-quarter 2026 results were not located, and Nasdaq listing status, dilution and Liquidity are the main risks to monitor.

Where Things Stand

The stock is lower on the pre-market quote, but no company-driven reason has surfaced to call it a lasting fade. Arcadia Biosciences (NASDAQ:RKDA) traded at USD 0.2060 in pre-market dealing on November 13, 2026, still about 42% above the October 19 close, and nothing explaining the move has been found. The company is small, with trailing Revenue near USD 4.75 million and a recent USD 4 million placement on the books. Next markers are the third-quarter report, any resale of registered shares and any Nasdaq compliance notice.